2024.09.16

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tolerated up to the highest […]

2024.09.10

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to begin in 1H 2025 ROCKVILLE, MD, September 11, 2024 […]

2024.08.28

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific) Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific) Well-positioned for […]

2024.08.26

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

ROCKVILLE, MD, August 26, 2024 – I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. H.C. Wainwright 26th Annual Global Investment Conference […]

2024.08.07

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP(PwC)

Engagement is part of I-Mab’s commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, MD, August 7, 2024 – I-Mab (NASDAQ: IMAB) (“I-Mab”, the “Company”), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the […]

2024.07.15

I-Mab Announces Leadership Transitions

ROCKVILLE, MD, July 15, 2024 – I-Mab (NASDAQ: IMAB) (the “Company” or “I-Mab”), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. Wei Fu as the Chairman of the Board of Directors. He succeeds Dr. Pamela M. Klein, who steps down from I-Mab’s Board of Directors […]

2024.06.06

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

ROCKVILLE, MD, June 6, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, […]

2024.06.05

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. Collaboration builds on promising safety and efficacy data from the givastomig monotherapy study reported at the European Society of Medical Oncology Congress 2023. ROCKVILLE, […]

2024.05.23

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

– Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitors – Phase 1 dose-escalation data demonstrated that ragistomig monotherapy can be safely administered through the highest planned doses – Data will be presented at the 2024 Annual […]

2024.05.22

I-Mab to Participate at the Jefferies Global Healthcare Conference

ROCKVILLE, MD, May 22, 2024 – I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024. Jefferies Global Healthcare Conference Presentation Time Wednesday, June […]